Skip to main content
  1. Right Decisions
  2. DGRefHelp - NHS Dumfries & Galloway
  3. Sexual health
  4. Back
  5. Sexually transmitted infections (STIs)
  6. Trichomonas Vaginalis
Important: please update your RDS app to version 4.7.3 Details with newsletter below.

Please update your RDS app to v4.7.3

We asked you in January to update to v4.7.2.  After the deployment planned for 27th February, this new update will be needed to ensure that you are able to download RDS toolkits even when the RDS website is not available. We will wait until as many users as possible have downloaded the new version before switching off the old system for app downloads and moving entirely to the new approach.

To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number. 

To update to the latest release:

 On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.

On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.

Right Decision Service newsletter: February 2025

Welcome to the February 2025 update from the RDS team

1.     Next release of RDS

 

A new release of RDS is planned (subject to outcomes of current testing) for week beginning 24th February. This will deliver:

 

  • Fixes to mitigate the recurring glitches with the RDS admin area and the occasional brief user interface outages which have arisen following implementation of the new distributed technology infrastructure in December 2024.

 

  • Capability to embed content from Google calendar, Google Maps, Daily Motion, Twitter feeds, Microsoft Stream into RDS pages.

 

  • Capability to include simple multiplication in RDS calculators.

 

The release will also incorporate a number of small fixes, including:

  • Exporting of form within Medicines Sick Day Guidance in polypharmacy toolkit
  • Links to redundant content appearing in search in some RDS toolkits
  • Inclusion of accordion headers alongside accordion text in search result snippets.
  • Feedback form on mobile app.
  • Internal links on mobile app version of benzo tapering tool

 

We will let you know when the date and time for the new release are confirmed.

 

2.     New RDS developments

There is now the capability to publish toolkits on the web with left hand side navigation rather than tiles on the homepage. To use this feature, turn on the “Toggle navigation panel” option at the top of the Page settings menu at toolkit homepage level – see below. Please note that publication to downloadable mobile app for this type of navigation is still under development.

The Benzodiazepine tapering tool (https://rightdecisions.scot.nhs.uk/benzotapering) is now available as part of the RDS toolkit for the national benzodiazepine prescribing guidance developed by the Scottish Government Effective Prescribing team. The tool uses this national guidance developed with a wide-ranging multidisciplinary group. This should be used in combination with professional judgement and an understanding of the needs of the individual patient.

3.     Archiving and version control and new RDS Search and Browse interface

Due to the intensive work Tactuum has had to undertake on the new technology infrastructure has pushed back the delivery dates again and some new requirements have come out of the recent user acceptance testing. It now looks likely to be an April release for the search and browse interface. The archiving and version control functionality may be released earlier. We’ll keep you posted.

4.     Statistics

At the end of January, Olivia completed the generation of the latest set of usage statistics for all RDS toolkits. If you would like a copy of the stats for your toolkit, please contact Olivia.graham@nhs.scot .

 

5.     Review of content past its review date

We have now generated reports of all RDS toolkit content that has exceeded its review date by 6 months or more. We will be in touch later this month with toolkit owners and editors to agree the plan for updating or withdrawing out of date content.

 

6.     Toolkits in development

Some important toolkits in development by the RDS team include:

  • National CVD prevention pathways – due for release end of March 2025.
  • National respiratory pathways, optimal cancer diagnostic pathways and cancer prehabilitation pathways from the Centre for Sustainable Delivery. We will shortly start work on the national cancer referral pathways, first version due for release via RDS around end of June 2025.
  • HIS Quality of Care Review toolkit – currently in final stages of quality assurance.

 

The RDS team and other information scientists in HIS have also been producing evidence summaries for the Scottish Government Realistic Medicine team, to inform development of national guidance around Procedures of Limited Clinical Value. This guidance will in due course be translated into an RDS toolkit.

 

7. Training sessions for new editors (also serve as refresher sessions for existing editors) will take place on the following dates:

  • Friday 28th February 12-1 pm
  • Tuesday 11th March 4-5 pm

 

To book a place, please contact Olivia.graham@nhs.scot, providing your name, organisation, job role, and level of experience with RDS editing (none, a little, moderate, extensive.)

 

To invite colleagues to sign up to receive this newsletter, please signpost them to the registration form  - also available in End-user and Provider sections of the RDS Learning and Support area.   If you have any questions about the content of this newsletter, please contact his.decisionsupport@nhs.scot  If you would prefer not to receive future newsletters, please email Olivia.graham@nhs.scot and ask to be removed from the circulation list.

With kind regards

 

Right Decision Service team

Healthcare Improvement Scotland

 

 

Trichomonas Vaginalis

Warning

What’s New

Recommended treatment is 7 day course of metronidazole. Stat dose has a higher rate of
treatment failure.

Introduction

Trichomonas vaginalis (TV) is a flagellated protozoan that is a parasite of the genital tract.

Due to site specificity, infection almost always follows direct inoculation of the organism (intravaginal or intraurethral) and is thus almost exclusively sexually transmitted.

Note: there are other species of Trichomonas which are not sexually transmitted, eg, Trichomonas Faecalis, so it is therefore important to clarify this with the testing laboratory if further differentiation is required.

In adult female cases urethral infection is present in 90% of episodes, although the urinary tract is the sole site of infection in <5% cases.

In men infection is usually of the urethra.

The most obvious host response to infection is a local increase in polymorphs.

Infection is associated with an increased risk of HIV transmission.

There is a spontaneous cure rate in the order of 20/25%.

TV should be managed in local specialist sexual health services or in consultation with.

This guidance is aimed primarily at people aged 16years or older.

Symptoms & Signs in Females

Symptoms (10-50% asymptomatic)

  • Vaginal discharge
  • Itch
  • Dysuria
    Burning
  • Occasionally lower abdominal discomfort or vulval ulceration

Signs (5-15% nil abnormal on examination)

  • Erythema – vaginitis and vulvitis
  • Discharge – in up to 70%. The classical frothy yellow discharge is seen in 10-30% of females.
  • Odour
  • 2% “strawberry” cervix visible to the naked eye

Symptoms & Signs in Males

Symptoms (15-50% asymptomatic; Often present as contacts of infected female partners)

  • Urethral discharge
  • Dysuria
  • Frequency

Signs

  • Urethral discharge
  • Rarely balanoposthitis

Diagnosis in Females

It is important to check with your local laboratory if they have facilities for culture of TV and how to request this is done. Some laboratories will do microscopy alone for TV.

Females – Investigations

  • Vaginal pH – Use a swab/loop to collect discharge from the lateral vaginal wall and put it on narrow range pH paper (range 3.8-5.5). TV is associated with an elevated vaginal pH of > 4.5
  • IMMEDIATE microscopy (where available) Sensitivity 45-60%
    • Wet mount preparation (normal saline) from posterior vaginal fornix
    • Read within 10 minutes of collection – motility decreases with time
    • Direct observation of trichomonas
  • Where IMMEDIATE microscopy is not available:
    • The diagnosis may be made provisionally if there is profuse frothy discharge, vaginitis and a raised pH
  • HVS (from posterior fornix) should arrive in the lab within 6 hours
  • Culture of TV Specific culture media will diagnose up to 95% cases
  • Point of care tests are available. False positives may occur especially in populations of low prevalence – consider confirming positives in this situation
  • Nucleic acid amplification tests (NAATS) are available for diagnosis of TV. These offer the highest sensitivity. These should be the test of choice where resources allow
  • Offer full STI testing

NB: Be aware that TV diagnosed on Liquid based cytology may have a false positive rate. If TV-like organisms are reported via SCCRS, a letter is generated via the results service requesting the woman to attend to confirm infection prior to any treatment and/or partner notification.

Diagnosis in Males

In practice, treatment is usually epidemiological without identification of the organism, which is difficult - highest yield is from centrifuged first void urine deposit.

  • Microscopy of urethral smear in saline gives a diagnosis in 30% of infected males
    • If there is an excess of polymorphs on initial microscopy, repeat urethral smear after TV treatment is complete. This will allow a separate diagnosis of Non-specific urethritis
  • Doing both a urethral swab culture (using specific culture media) and a culture of first void urine can increase the diagnostic rate (urine should not be refrigerated and ideally should be centrifuged within an hour)
  • Nucleic acid amplification tests (NAATS) are available for diagnosis of TV. These offer the highest sensitivity. These should be the test of choice where resources allow.
  • Offer full STI testing

Treatment

  • 95% response
  • Treat partners simultaneously irrespective of test results
  • Note spontaneous cure rate in the order of 20-25%

Preferred treatment: Metronidazole 400-500mg twice daily for 5-7 days
Alternative treatment: Metronidazole 2g stat (stat dose has a higher risk of treatment
failure)
Advise to avoid alcohol for the duration of treatment and for 48 hours
afterwards with metronidazole

  • Clients should be advised to avoid sexual intercourse (including oral sex) for at least 1 week until they and their partner(s) has completed treatment and follow-up
  • Give detailed information about the condition. The following is a link to the BASHH Patient Information leaflet Trichomonas Vaginalis

Partner Notification

  • All clients diagnosed with TV should see a sexual health specialist who has achieved
    sexual health advisor competencies
  • Current sexual partners should be treated for TV and offered testing for STIs regardless of the results of their tests
  • Epidemiological treatment for partners is as above
  • Any partner(s) within the 4 weeks prior to presentation should be treated

Follow up in Females

  • Telephone consultation at 2 weeks with a sexual health specialist with sexual health advising competencies to check compliance, when they last had sex, and if they have any ongoing symptoms
  • If still symptomatic, arrange a test of cure. Optimum timing is 4 weeks after start of treatment
  • Complete Partner Notification
  • Ensure offered/ arranged testing for HIV and Syphilis taking into account relevant window period and risk exposure

Follow-up in Males

  • Telephone consultation at 2 weeks with a sexual health specialist with sexual health advising competencies to check compliance, when they last had sex, and if they have any ongoing symptoms
  • If there was an excess of polymorphs on initial urethral microscopy repeat this at follow up to ensure a diagnosis of non-specific urethritis has not been missed
  • If still symptomatic, arrange a test of cure. Optimum timing is 4 weeks after start of treatment
  • Complete Partner Notification
  • Ensure offered/ arranged testing for HIV and Syphilis taking into account relevant window period and risk exposure

Recurrent / Relapsing Trichomonas Vaginalis

May be due to inadequate therapy, re-infection or resistance.

  1. Confirm partner(s) has been treated and that they have abstained from sexual contact
  2. Check compliance with therapy and exclude vomiting from metronidazole
  3. Once re-infection and non-compliance has been excluded:

 

1. Repeat course of Metronidazole – 400-500 mg twice daily for 7 days
2. For patients failing 1. Try Metronidazole 2g daily orally for 5 to 7 days or 800mg three times daily for 7 days

If patient fails on the above 2 options discuss with a senior colleague in GUM before considering alternative options. 

Trichomonas Vaginalis in Pregnancy

See West of Scotland Managed clinical Network Guideline on Trichomonas vaginalis in Pregnancy  

References

British Association for Sexual Health and HIV (BASHH) United Kingdom national guideline on the management of Trichomonas vaginalis 2021 (cited 2023 May) 

Sherrard J, Wilson J, Donders G, Mendling W, Jensen JS. 2023 update to 2018 European (IUSTI/WHO) guideline on the management of vaginal discharge. International Journal of STD & AIDS. 2023;34(10):745-745. doi:10.1177/09564624231179277 (cited 2023 May)

 

Editorial Information

Last reviewed: 31/05/2023

Next review date: 31/01/2025

Author(s): West of Scotland Managed Clinical Network in Sexual Health Clinical Guidelines Group .

Version: 7.1

Approved By: West of Scotland Managed Clinical Network in Sexual Health